[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651659":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":7,"responsibleParty":18,"collaborators":7,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":7,"acronym":7,"eligibilityCriteria":25,"healthyVolunteers":22,"sex":7,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":26,"phases":7,"briefSummary":27,"conditions":28,"keywords":7,"overallStatus":30,"whyStopped":7,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":35,"locationsCount":7},{"fullName":5,"class":6},"Idorsia Pharmaceuticals Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Lucerastat",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Idorsia Clinical Trials Information","CONTACT","+1 856 661 37 21","idorsiaclinicaltrials@idorsia.com",{"type":19,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100651659","post-trial-access-to-lucerastat-for-patients-with-fabry-disease-who-participated-in-study-id-069a302-100651659",false,"NCT07762638","Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","This is a Post Trial Access program for patients with Fabry Disease who previously participated in the ID-069A302 (MODIFY OLE) trial and who were still enrolled in the study at the time the Sponsor decided to discontinue ID-069A302. The program is designed to provide continued access to lucerastat.",[29],"Fabry Disease","AVAILABLE","2026-08-07",{"date":33,"type":34},"2026-08-13","ACTUAL",{"name":5,"class":6}]